Niusule Biotech Corporation, is a fast growing China-based bio-pharmaceutical company with a primary concentration on animal health products, in addition to its human nutraceutical supplement business, has announced that the Company acquired an additional 14% equity interest in Tianjin Behigh Pharmaceutical Co. Ltd. ("Tianjin Behigh"). Tianjin Behigh is an animal health company in business for more than ten years, recognized by the agricultural industry for its excellence in quality and technology. The acquisition increases the Company's overall equity interest in Tianjin Behigh to 59%.
Management believes that market demand for livestock products in China has been stimulated by the rapid urbanization and increase in disposable income throughout the country. According to the "Veterinary Drugs Market Guide" published in 2009, the growth rate of the farming industry in China is 12-15%, which is more than that of developed countries. For more information, please visit http://www.sysczn.com/. The manufacturers of veterinary drugs should benefit directly from this market expansion. Management believes that the concern for safe, high quality, nutritional, and pollution-free green products has become the consensus of the consumers of veterinary products and is becoming the basic driving force for the development of the veterinary drugs industry.
Ms. Amy Hu, President and CEO of Niusule commented, "We believe that the animal health products industry in China is promising and will grow rapidly in the next ten years. Our increased stake in Tianjin Behigh is a key milestone for our company to become an important factor in China's animal health business. According to the 'Veterinary Drugs Market Guide,' the market size is $450 to $600 million annually in China for the animal health sector. We strongly believe the acquisition will further support our position as a leading high-quality healthcare product company in both the animal and human health markets. A key part of our business strategy is to acquire entities with an established brand, profitable operations, and a product portfolio with significant commercialization value that complement our existing business."
Mr. Peizhu Fan, Chairman and CEO of Tianjin Behigh commented, "We are pleased to be part of Niusule as it will enable us to leverage our growing marketing power and operating resources available for new animal health product launches. We look forward to the benefits associated with the acquisition and believe it provides us with a strong platform for sales and profitability growth in the future."
About Niusule Biotech Corp.
Niusule Biotech Corp. is a bio-pharmaceutical company dedicated to offering high-quality pharmaceutical and nutritional supplement products to enhance both animal and human health. The Company has recently acquired a majority interest in Tianjin Behigh Pharmaceutical Co., Ltd, a veterinary drug and feed additives manufacturing company that produces injections, tablets, granules, oral solutions, powder, pelvis, and disinfectant for animal use. For the human product line, Niusule currently has a retail distribution network throughout China comprised of 124 outlets at high-end supermarkets and shopping malls in Zhejiang province, Shanghai and Beijing. For more information about Niusule Biotech Corp., please visit http://www.niusule.com/.
About Tianjin Behigh Pharmaceutical Co. Ltd.
Tianjin Behigh Pharmaceutical Co. Ltd. Located and founded in Tianjin, China in 1999, Tianjin Behigh Pharmaceutical is known for its animal health products which emphasize quality and safety. The Company has a state-of-the-art GMP manufacturing facility and R&D lab located at its headquarters. Tianjin Behigh has successfully developed 183 veterinary drugs and feed additives used heavily in the agricultural industry throughout China. The Company will continue to be managed by its founder and CEO, Mr. Peizhu Fan, and by his management team which has extensive animal product development and sales expertise. For more information on Tianjin Behigh, please visit http://www.behigh.com.cn/.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," "project," "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. Niusule Biotech Corp. does not assume any duty to publicly update or revise the material contained herein.